OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB:ISCO) announced today that its human parthenogenetic stem cell lines will be used in Germany in studies aimed at creating specific cell types to treat human neural diseases such as Parkinson’s disease.
